2-氨基噻吩-3-甲酸叔丁酯 | 59739-05-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 2-氨基噻吩-3-甲酸叔丁酯
• 中文别名: 2-氨基噻吩-3-羧酸叔丁酯
• 英文名称: tert-butyl 2-aminothiophene-3-carboxylate
• CAS: 59739-05-8
• 化学式: C₉H₁₃NO₂S
• mdl: MFCD03095194
• 分子量: 199.274
• InChiKey: MMDNHEKRFNBVIM-UHFFFAOYSA-N

物化性质

• 沸点：
  289.6±20.0 °C(Predicted)
• 密度：
  1.181±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  80.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Aminothiophene-3-carboxylic acid t-butyl ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Aminothiophene-3-carboxylic acid t-butyl ester
CAS number: 59739-05-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H13NO2S
Molecular weight: 199.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基噻吩-3-甲酸叔丁酯 在 苯膦酰二氯 、 溶剂黄146 、 锌 作用下， 以 二苯醚 、 甲苯 为溶剂， 反应 5.17h， 生成 噻吩并[2,3-b]吡啶
  参考文献：
  名称：

  Barker, John M.; Huddleston, Patrick R.; Holmes, David, Journal of Chemical Research, Miniprint, 1985, # 7, p. 2501 - 2523

  摘要：

  DOI：
• 作为产物：
  描述：

  1,4-二硫-2,5-二醇 、 氰乙酸叔丁酯 在 Bacillus licheniformis alkali protease 作用下， 以 水 为溶剂， 以94.7 %的产率得到2-氨基噻吩-3-甲酸叔丁酯
  参考文献：
  名称：

  离子液体中酶催化的 Gewald 反应高效合成 2-氨基噻吩

  摘要：

  开发了一种绿色高效的碱性蛋白酶脂肪酶-离子液体体系来催化2,5-二羟基-1,4-二噻烷与不同取代的活化腈之间的Gewald反应。在 50 °C 下合成了一系列 3-取代 2-氨基噻吩，产率中等至良好 (67.8–97.4%)。值得注意的是，观察到催化系统循环 10 次，收率没有任何损失，这是一个良好的回收实验。结合回收结果，证明了脂肪酶-离子液体体系的稳定性和方案的实用性。

  DOI：

  10.1016/j.molstruc.2023.136511

文献信息

• 4-oxo-4,7-dihydro-thieno[2,3-b]pyridine-5carboxamides as antiviral agents
  申请人：Pharmacia & Upjohn Company

  公开号：US06239142B1

  公开（公告）日：2001-05-29

  The invention provides a compound of formula I: wherein R1, R2, R3, and R4 have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of preventing or treating a herpesvirus infection using such compounds or salts.

  该发明提供了一个式I的化合物：其中R1、R2、R3和R4具有规范中定义的任何值，或其药用可接受盐，以及用于制备这些化合物或盐的有用中间体和过程，以及使用这些化合物或盐预防或治疗疱疹病毒感染的方法。
• Synthesis and biological evaluation of 2-acetamidothiophene-3-carboxamide derivatives against Leishmania donovani
  作者：Sangmi Oh、Bosung Kwon、Sunju Kong、Gyongseon Yang、Nakyung Lee、Dawoon Han、Junghyun Goo、Jair L. Siqueira-Neto、Lucio H. Freitas-Junior、Michel Liuzzi、Jinhwa Lee、Rita Song

  DOI：10.1039/c3md00299c

  日期：——

  A high-throughput (HTS) and high-content screening (HCS) campaign of a commercial library identified 2-acetamidothophen-3-carboxamide as a novel scaffold for developing new anti-leishmanial agents. A series of chemical modifications were performed to study the structure–activity relationship (SAR) and in vitro anti-leishmanial activities were evaluated using biological assays of not only extracellular promastigotes but also intracellular amastigotes. Compound 6a showed promising anti-amastigote activity (EC50 = 6.41 μM) against L. donovani without any cytotoxicity (CC50 > 50 μM) towards human macrophages.

  商业图书馆的高通量（HTS）和高内涵筛选（HCS）活动确定了 2-acetamidothophen-3-carboxamide 作为开发新型抗利什曼病药物的新型支架。进行了一系列化学修饰来研究构效关系（SAR），并使用细胞外前鞭毛体和细胞内无鞭毛体的生物测定来评估体外抗利什曼原虫活性。化合物 6a 对杜氏乳杆菌表现出良好的抗无鞭毛体活性 (EC50 = 6.41 μM)，而对人巨噬细胞没有任何细胞毒性 (CC50 > 50 μM)。
• 4-OXO-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：US20020006937A1

  公开（公告）日：2002-01-17

  The invention provides a compound of formula I: 1 wherein R 1 , R 2 , R 3 , and R 4 have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of preventing or treating a herpesvirus infection using such compounds or salts.

  本发明提供了化合物I的公式：1其中R1，R2，R3和R4具有规范中定义的任何值，或其药学上可接受的盐，以及用于制备这些化合物或盐的有用中间体和方法，以及使用这些化合物或盐预防或治疗疱疹病毒感染的方法。
• Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity
  申请人：Hodson Francis Harold

  公开号：US20050075336A1

  公开（公告）日：2005-04-07

  The use of a compound comprising formula (I), or a salt, ester, amide or prodrug thereof in the treatment of obesity and related disorders. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I): A is an optionally substituted thienyl moiety, Y is O, S, or NR 2 , R 1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups and R 2 is hydrogen or a group as defined for R 1 .

  使用具有式（I）的化合物，或其盐，酯，酰胺或前药治疗肥胖症及相关疾病。本发明还涉及公式（I）内的新化合物，制备它们的方法以及含有它们的制药组合物。在公式（I）中：A是可选择取代的噻吩基团，Y是O，S或NR2，R1是支链或非支链烷基（可被一个或多个氧原子中断），烯基，炔基，环烷基，环烷烯基，芳基，芳基烷基，还原芳基烷基，芳基烯基，杂环芳基，杂环芳基烷基，还原杂环芳基，还原杂环芳基烷基或任何上述基团的取代衍生物，R2是氢或与R1定义相同的基团。
• Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof
  申请人：Evans Karen

  公开号：US20070249670A1

  公开（公告）日：2007-10-25

  The invention relates to glycogen phosphorylase inhibitor compounds, pharmaceutical compositions of these compounds, methods of treatment using the pharmaceutical compositions to treat diabetes, conditions associated with diabetes, and/or tissue ischemia, including myocardial ischemia, and processes for making the compounds.

  本发明涉及糖原磷酸化酶抑制剂化合物、这些化合物的药物组合物、使用这些药物组合物治疗糖尿病、与糖尿病相关的疾病和/或组织缺血，包括心肌缺血的方法，以及制备这些化合物的过程。